Biosimilars for the management of rheumatoid arthritis: Economic considerations

László Gulácsi, Valentin Brodszky, Petra Baji, Ho Ung Kim, Su Yeon Kim, Yu Young Cho, Márta Péntek

Research output: Contribution to journalReview article

50 Citations (Scopus)


Biologic drugs have proved highly effective for the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA). These drugs are often considered cost-effective for well-defined RA patient populations not responding adequately to conventional treatment, but are used first-line relatively rarely, partly due to high costs. Furthermore, not all clinically eligible patients can access biologics even as second-line therapy. Recently, there has been a rise in interest in biosimilar drugs that are highly comparable to the reference medicinal product (RMP) in terms of efficacy and safety but may generally be lower in price. This review summarizes the cost burden of RA and considers the potential role of biosimilars in reducing drug costs and increasing patient access to biologics.

Original languageEnglish
Pages (from-to)S43-S52
JournalExpert review of clinical immunology
Publication statusPublished - Sep 28 2015



  • CT-P13
  • biosimilar
  • budget savings
  • cost-effectiveness
  • pharmacoeconomics
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this